Johnson & Johnson reach $117m settlement over misleading marketing
Johnson & Johnson has settled a multi-state legal action brought against it in the US over allegations it misled patients and healthcare providers in its marketing of surgical devices.
Johnson & Johnson reach $117m settlement over misleading marketing
The medical giant has agreed to pay $116.9m to 41 states and the District of Columbia for allegedly misrepresenting the safety and effectiveness of its transvaginal surgical mesh devices.
Separate lawsuits brought by four other US states remain pending.
Earlier this year the Food and Drug Administration banned the sale of all implants following a spate of personal injury settlements totaling some $8bn.
It is claimed that Johnson & Johnson failed in its duty to disclose the risks associated with the products, which are also administered to treat bladder issues.
Johnson & Johnson has been embroiled in several recent scandals including its role in an ongoing opioid crisis. In June the firm moved to streamline its operations by scrapping its global CMO role.
Content created with:
Johnson & Johnson
Find out more